Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01258998 · OUTCOME

Progression-free Survival

Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma · Source last updated 2020-11-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
From treatment start date until the date of first documented progression or date of death from any cause, whichever came first.

What was measured

Kaplan-Meier method was used. The log-rank test was performed to test the difference in time-to-event distributions between patient groups. Cox proportional hazards model was used to include multiple covariates in the time-to-event analysis.

Groups in this outcome

Akt Inhibitor MK2206

Akt inhibitor MK2206 200 mg orally once a week, repeats every 28 days for up to 12 courses.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Akt Inhibitor MK220659

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Akt Inhibitor MK22062.8Not reported26Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        2
        upper Limit
        6
        value
        2.8
denoms
  1. counts
    1. group Id
      OG000
      value
      59
    units
    Participants
description
Kaplan-Meier method was used. The log-rank test was performed to test the difference in time-to-event distributions between patient groups. Cox proportional hazards model was used to include multiple covariates in the time-to-event analysis.
dispersion Type
95% Confidence Interval
groups
  1. description
    Akt inhibitor MK2206 200 mg orally once a week, repeats every 28 days for up to 12 courses.
    id
    OG000
    title
    Akt Inhibitor MK2206
param Type
MEDIAN
reporting Status
POSTED
time Frame
From treatment start date until the date of first documented progression or date of death from any cause, whichever came first.
title
Progression-free Survival
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice